CervoMed Inc. Cash Flow Statement
CRVO|4 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
CervoMed Inc. used $23M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2011 |
|---|---|---|---|---|
| Net Income | -$27.0M | -$2.2M | -$5.8M | -$15.8M |
| Depreciation & Amortization | - | - | - | $69.8K |
| Operating Cash Flow | -$23.4M | -$7.4M | -$2.6M | -$12.0M |